罗氏83亿收购美国制药公司InterMune.pptx

The Swiss drug maker Roche agreed on Sunday to buy InterMune — which sells a drug to treat a deadly lung disease — for $8.3 billio on, as pharmaceutical companies continue to seek new products to bolster their offerings. 在制药企业纷纷寻求以新药扩充产品类别之际，瑞士药企罗氏公司(Roche)周日同意 以83亿美元收购InterMune，后者拥有一款药品，可以治疗致命的肺部疾病。 The price, $74 a share, represents a 38 percent premium to InterMune’s closing price on Fr iday and a 63 percent premium to the price on Aug.12, before news reports that InterMune might be acquired. 上述交易的收购价为每股74美元（约合455元 人民币），较InterMue周五的收盘价溢价38%，较收购消息传出前8月12日的股价溢价63%。 The acquisition was announced during a flurry of pharmaceutical deals and attempt ed deals. About $87 billion in pharmaceutical acquisitions were made in the first half of this year, eclipsing the total for all o f 2013, according to Evaluate, a research company. The total for the first half does not include the $54 billion acquisition of Sh ire by AbbVie, which was formally announced in July. 罗氏公司宣布上述交易的同时，制药行业的交易数量出现了猛增。研究公司Evaluate的数据显示，今年上半年，该行业的收购交易总额约为870亿美元，超过了20 13全年的规模。这还不包括7月正式宣布的艾伯维(AbbVie)收购沙尔制药(Shire)的540亿美元的交易。 InterMune, based in Brisbane, Calif., has one product on the market: a dru g called pirfenidone to treat idiopathic pulmonary fibrosis, a fatal scarring of the lungs. InterMune总部设在加州布里斯班，在市场上只有一款产品：吡非尼酮。该药 治疗的是特发性肺纤维化，一种可导致肺部结痂的致命疾病。 InterMune, which is still not profitable, sells pirfenidone under the name Esbriet in Europe and Canad a, where it received regulatory approval in 2011 and 2012. The drug could receive approval in the United States by Nov. 23. 尚未盈利的I nterMune于2011年和2012年分别在欧洲和加拿大获得了监管机构的批准，以品牌名称Esbriet销售吡非尼酮。该药品可能会于11月23日前在美国获批。 Sales of Esbriet were $35.7 million in the second quarter, but some analysts expect annual revenues to eventually exceed $1 billion. Esbriet的第二季度销售额为3570万美元，但分析师预计，该产品的年度营收最终会超过10亿 美元。 “We are obviously focused on high unmet medical needs and looking for medicines that make a significant difference clinically, and this clearly fits that bill,”